STABLE FORMULATION OF HUMAN PAPILLOMAVIRUS VIRUS-LIKE PARTICLE VACCINE

Provided is a stable formulation of a human papillomavirus virus-like particle vaccine. The stable formulation is composed of a human papillomavirus virus-like particle, a buffer solution, an osmotic pressure regulator, a surfactant and an aluminum adjuvant, wherein the components of the vaccine comprise HPV virus-like particles assembled by L1 proteins of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and one or more HPV virus-like particles assembled by L1 proteins of other pathogenic HPV types. The formulation can enhance the stability of the vaccine and prolong the validity period of the vaccine in an aqueous formulation..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 07. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

LIU YAN [VerfasserIn]
HU PING [VerfasserIn]
CHANG XINRONG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-07, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29

Patentnummer:

US2024075124

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA001185942